Costs and outcomes for Parkinson’s disease patients who have their management adjusted by Personal KinetiGraph (PKG)
Objective: To quantify the potential cost savings and quality adjusted life years (QALYs) gained for people with Parkinson’s disease in Australia whose oral therapy was…The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations
Objective: To present the detailed clinical features of a patient with familial MSA carrying compound heterozygous COQ2 mutations and report the outcome of a high-dose ubiquinol…The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of highly-selective metabotropic glutamate 2 receptor (mGluR2) activation at alleviating and preventing the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Chronic…Speech and voice response to levodopa in late-stage Parkinson’s Disease patients: report from an acute levodopa challenge
Objective: to assess the change of speech and voice after an acute L-dopa challenge in late-stage Parkinson’s disease (LSPD). Background: PD patients are classically affected…Dextrometorphan/quinidine in Atypical Parkinsonisms and Huntington Disease
Objective: to determine whether Dextrometorphan/quinidine (DMQ) is effective in the treatment of PBA, AG or bulbar symptoms in corticobasal syndrome (CBS), multiple system atrophy (MSA),…Use of pimavanserin in patients with Parkinson’s disease psychosis: Subgroup analysis of efficacy and safety in patients with and without cognitive impairment
Objective: A planned subgroup analysis of a phase 3 study was performed to evaluate the efficacy and safety of pimavanserin (PIM) in Parkinson’s disease psychosis…Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.
Objective: To investigate if there is a significant relationship between weight loss in persons with Parkinson’s disease and side-effect incidence, and if so to what…Development of a Clinician-reported Screening Tool to Identify Patients with Parkinson’s disease inadequately controlled on oral medications
Objective: To identify key clinical indicators for Parkinson disease (PD) patients inadequately controlled with oral medications or eligible for device-aided treatments. Background: Identifying patients with…Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease
Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 34
- Next Page »